Data are provided as n, unless indicated otherwise. SCIT: subcutaneous immunotherapy; SD: standard deviation; AR: Allergic rhinitis; AC: Allergic conjunctivities; IBS: irritable bowel syndrome; V0: patients at the first visit; V1: patients at 1-year follow up; COVID-19: coronavirus disease 2019.

¹AIT was given by increased dose every 1-2 weeks until the maximum tolerated dose of the individual was reached.

² The maximum tolerated dose of the patients was given subcutaneously every 4-6 weeks for 2 years.

^* P value of < 0.05 was considered as statistically significant.